She was on dialysis for a period of 10 days, till her father was identified as a donor. She got her transplant in the year 2012.

Today, in the second innings of her life, she is managing this condition with acceptance, will power and discipline. Despite living with this condition, she was able to complete her PhD! On a treatment level, she is managing her diabetes with short-acting Insulin and long-acting insulin Glargine as recommended by doctors, which offers better glucose control and consequently, helps her to manage her diabetic CKD condition.

Co-developed by Biocon along with Mylan, Insulin Glargine is Biocon’s second-big milestone towards realizing its aspiration of reaching ‘one in five’ insulin dependent people with diabetes worldwide. Among the first few to receive approval for biosimilar Insulin Glargine in Europe, it is prescribed for adults with Type 2 diabetes as well as adults and pediatric patients (children 2 years and older) with Type 1 diabetes. For millions of patients with diabetes worldwide, it now opens up a new course of accessible and affordable insulin care.

“It’s a whole new life and I am learning how to handle it, every day,” says a happier Pooja. “If there’s anything I’d like people to learn from my story, it’s that you should not run away from your problems… Face them instead. Hope always exists… You just need to believe it does!”